The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, Rasheduzzaman, Yeoh, Kar Kheng, Tian, Ya‐Min, Hillringhaus, Lars, Bagg, Eleanor A, Rose, Nathan R, Leung, Ivanhoe K H, Li, Xuan S +10 more·2011·The EMBO Reports
DOI 10.1038/embor.2011.43

Cited by (1,000)

Items 801–900 of 1,000

  1. Suffocation of gene expression
    Dan Ye, Yue Xiong · 2016 · Nature
  2. Metabolic Reprogramming and Signaling to Chromatin Modifications in Tumorigenesis
    Zyanya Díaz-Hirashi, Tian Xiang Gao, Francisco Verdeguer · 2020 · Advances in experimental medicine and biology
  3. Metabolic Regulator IAPP (Amylin) Is Required for BRAF and RAS Oncogene-Induced Senescence
    Sam Garnett, Angeline de Bruyns, Veronique Provencher-Tom, Kendall Dutchak, Ran Shu, David L. Dankort · 2021 · Molecular Cancer Research
  4. Determination of intracellular 2-hydroxyglutarate enantiomers using two-dimensional liquid chromatography
    Takuma Ohtawa, Ayuna Hattori, Muneki Isokawa, Masashi Harada, Takashi Funatsu, Takahiro Ito, Makoto Tsunoda · 2021 · Journal of Chromatography Open
  5. The Metabolism of Cell Growth and Proliferation
    Lydia W.S. Finley, Craig B. Thompson · 2015 · Elsevier eBooks
  6. In Vitro Enzyme Assays for JmjC‐Domain‐Containing Lysine Histone Demethylases (JmjC‐KDMs)
    Hanna Tarhonskaya, Anthony Tumber, Akane Kawamura, Christopher John Schofield · 2018 · Current Protocols in Pharmacology
  7. Mitochondrial Processes in Targeted Cancer Therapy
    Radovan Krejčíř, Dalibor Valík, Bořivoj Vojtěšek · 2018 · Klinicka onkologie
  8. Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas
    Eric Lipp, Roger E. McLendon · 2018 · Seminars in Oncology Nursing
  9. Molecular Components of the RCC Grade
    Tatsuto Ishimaru · 2020 · Seminars in Nephrology
  10. Inhibition of a viral prolyl hydroxylase
    Gareth W. Langley, Martine I. Abboud, Christopher T. Lohans, Christopher John Schofield · 2019 · Bioorganic & Medicinal Chemistry
  11. Glutarate regulates T cell function and metabolism
    Eleanor Minogue, Pedro P. Cunha, Alessandro Quaranta, Javier Zurita, Shiv K. Sah‐Teli, Brennan J. Wadsworth, R. J. F. Hughes, Guinevere L. Grice, Pedro Veliça, David Bargiela et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  12. Exploring the oncogenic impact of heteroplasmic de novo MT-ND5 truncating mutations
    Yuanyuan Wu, Jiangbin Ye, Zhenglong Gu · 2025 · Mitochondrial Communications
  13. The role of epigenetic modifications in hematological cancers
    Jovana Ilic, Anna Bold, Stefan Tobias Knop · 2026 · Frontiers in Oncology
  14. IDH1 Mutation Impacts DNA Repair Through ALKBH2 Rendering Glioblastoma Cells Sensitive to Artesunate
    Olivier J. Switzeny, Stefan Pusch, Markus Christmann, Bernd Kaina · 2025 · Biomedicines
  15. Organic Acids Derived from Saliva-amalgamated Betel Quid Filtrate Are Predicted as a Ten-eleven Translocation-2 Inhibitor
    Devyani Bhatkar, Nistha Ananda, Kiran Bharat Lokhande, Kratika Khunteta, Priyadarshini Jain, Ameya Hebale, Sachin Chakradhar Sarode, Nilesh Kumar Sharma · 2023 · Journal of Cancer Prevention
  16. Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging
    Hui Fang, Eunsun Yu, Chang Liu, Christy Eapen, Chunming Cheng, Tianxiang Hu · 2025 · Seminars in Cancer Biology
  17. Fighting Fire with Fire in Cancer
    Thorsten Berger, Mary E. Saunders, Tak W. Mak · 2015 · Springer eBooks
  18. Convenient expression, purification and quantitative liquid chromatography-tandem mass spectrometry-based analysis of TET2 5-methylcytosine demethylase
    Mohit Jaiswal, Subhradeep Bhar, Harika Vemula, Swami Prakash, V. K. Chaithanya Ponnaluri, William G. Gutheil, Mridul Mukherji · 2017 · Protein Expression and Purification
  19. mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation
    Laura Wiehle, Günter Raddatz, Stefan Pusch, Julian Gutekunst, Andreas von Deimling, Manuel Rodríguez‐Paredes, Frank Lyko · 2017 · Cell Stress
  20. Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation
    Maël Heiblig, Sabine Khalife‐Hachem, Christophe Willekens, Jean‐Baptiste Micol, Angélo Paci, Virginie Penard‐Lacronique, Stéphane de Botton · 2020 · Expert Review of Precision Medicine and Drug Development
  21. 2-HG modulates glioma macrophages via Trp metabolism
    Marie Jo Halaby, Tracy L. McGaha · 2021 · Nature Cancer
  22. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction
    Xuechen Zhou, Mengzhu Zheng, Na Zhao, Yixin Hu, Kaiyin Yang, Junfeng Huo, Guangyuan Liu, Jiangeng Huang, Lixia Chen, Yirong Zhou et al. · 2021 · Bioorganic Chemistry
  23. Capturing the Dynamic Conformational Changes of Human Isocitrate Dehydrogenase 1 (IDH1) upon Ligand and Metal Binding Using Hydrogen–Deuterium Exchange Mass Spectrometry
    Kaitlyn A. Sabo, Elene Albekioni, Danielle Caliger, Nalani J. Coleman, Ella Thornberg, Diego Avellaneda Matteo, Elizabeth A. Komives, Steve Silletti, Christal Dyane Sohl · 2023 · Biochemistry
  24. An enzymic l-2-hydroxyglutarate biosensor based on l-2-hydroxyglutarate dehydrogenase from Azoarcus olearius
    Shuang Hou, Zhaoqi Kang, Yidong Liu, Chuanjuan Lü, Xia Wang, Qian Wang, Cuiqing Ma, Ping Xu, Chao Gao · 2023 · Biosensors and Bioelectronics
  25. Active site remodeling in tumor-relevant IDH1 mutants drives distinct kinetic features and potential resistance mechanisms
    Matthew Mealka, Nicole A. Sierra, Diego Avellaneda Matteo, Elene Albekioni, Rachel Khoury, Timothy Mai, Brittany M. Conley, Nalani J. Coleman, Kaitlyn A. Sabo, Elizabeth A. Komives et al. · 2024 · Nature Communications
  26. A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate
    Kristian A. Choate, Wren Konickson, Zoe Moreno, Olivia S. Brill, Brett C. Cromell, Bella M. Detienne, Matthew J. Jennings, Paul B. Mann, Robert J. Winn, David Olayinka. Kamson et al. · 2025 · BMC Cancer
  27. Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology
    Ariana Sabzevari, Johnson Ung, Jeffrey W. Craig, Kallesh Danappa Jayappa, Ipsita Pal, David J. Feith, Thomas P. Loughran, Owen A. O’Connor · 2025 · CA A Cancer Journal for Clinicians
  28. Interweaving Tumor Heterogeneity into the Cancer Epigenetic/Metabolic Axis
    Jia Yu Leung, Kimberly Chia, Derrick Sek Tong Ong, Reshma Taneja · 2019 · Antioxidants and Redox Signaling
  29. Epigenomics – Impact for Drug Safety Sciences
    Harri Lempiäinen, Raphaëlle Luisier, Arne Müller, Philippe Marc, David J. Heard, Federico Bolognani, Pierre Moulin, Philippe Couttet, Olivier Grenet, Jennifer L. Marlowe et al. · 2012
  30. Polyamine metabolism regulates the T cell epigenome through hypusination
    Daniel J. Puleston, Francesc Baixauli, David E. Sanin, Matteo Villa, Agnieszka Martyna Kabat, Marcin M. Kamiński, Hauke J. Weiss, Katarzyna M. Grzes, Lea J. Flachsmann, Cameron S. Field et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  31. L-2-hydroxyglutarate regulates centromere and heterochromatin conformation in the male germline
    Nina Mayorek, Miriam Schlossberg, Yousef Mansour, Nir Pillar, Ilan Stein, Fatima Mushasha, Guy Paz, Eleonora Medvedev, Zakhariya Manevitch, Julia Menzel et al. · 2025 · PLoS Genetics
  32. l-2-Hydroxyglutarate impairs neuronal differentiation through epigenetic activation of MYC expression
    Wen Gu, Xun Wang, Ashley Solmonson, Ling Cai, Yi Xiao, Alpaslan Tasdogan, Jordan Franklin, Yuannyu Zhang, Hua Zhang, Aundrea K. Westfall et al. · 2026 · Journal of Clinical Investigation
  33. Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications
    Yuhan Fang, Xiaoqing Wang, Kai Luo, Tikam Chand Dakal, He Bai, Caiming Xu, Guixin Zhang · 2026 · MedComm
  34. Tiny Messengers, Actionable Targets: sEV-Driven Epigenetic Changes in Cancer
    Nagendra Verma, Swati Arora, Katrina Croghan · 2026 · Targets
  35. Metabolic Changes and Their Characterization
    Noor-ul Ain, Hira Gull · 2020 · Springer eBooks
  36. Prediction of Tumor Development and Urine-Based Liquid Biopsy for Molecule-Targeted Therapy of Gliomas
    Michihiro Kurimoto, Yumi Rockenbach, Akira Kato, Atsushi Natsume · 2023 · Genes
  37. Trans vs. cis : a computational study of enasidenib resistance due to IDH2 mutations
    Erik Lindahl, Erik Arvidsson, Ran Friedman · 2024 · Physical Chemistry Chemical Physics
  38. Distinct Essentiality of the Mitochondrial Respiratory Chain in Proliferating Cells In Vivo
    Claudie Bosc, Navdeep S. Chandel · 2024 · Annual Review of Cancer Biology
  39. Design, synthesis and biological evaluation of novel 5-hydroxy-2-methyl-4 H -pyran-4-one derivatives as antiglioma agents
    Yibin Li, Wen Sheng Hou, Hui Lin, Pinghua Sun, Jing Lin, Wei‐Min Chen · 2018 · MedChemComm
  40. Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
    Florence Pasquier, Claude Chahine, Christophe Marzac, Stéphane de Botton · 2020 · Expert Review of Precision Medicine and Drug Development
  41. Allele‐Specific Inhibition of Histone Demethylases
    Shana Wagner, Megan Waldman, Simran Arora, Sinan Wang, Valerie Scott, Kabirul Islam · 2019 · ChemBioChem
  42. Upstaging and Downstaging in Gliomas—Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System
    Oana Gabriela Trifanescu, Raluca Alexandra Trifanescu, Radu Iulian Mitrica, Dan Mitrea, Ana Ciornei, Mihai Géorgescu, Ioana Butnariu, Laurentia Nicoleta Gales, Luiza Georgia Serbanescu, Rodica Maricela Anghel et al. · 2023 · Diagnostics
  43. Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity
    Padma Kadiyala, Stephen V. Carney, Jessica C. Gauss, María Belén Garcia-Fabiani, Felipe Javier Núñez, Fernando M. Núñez, Mahmoud S. Alghamri, Yayuan Liu, Minzhi Yu, Dan Li et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  44. 2-hydroxyglutarate controls centromere and heterochromatin conformation and function in the male germline
    Nina Mayorek, Miriam Schlossberg, Yousef Mansour, Nir Pillar, Ilan Stein, Fatima Mushasha, Guy Baziza, Eleonora Medvedev, Zakhariya Manevitch, Julia Menzel et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  45. Metabolic Reprogramming in Cancer
    Debasish Prusty, Soumen K. Manna · 2022 · Wiley eBooks
  46. Methionine availability influences essential H3K36me3 dynamics during cell differentiation
    Yudong Sun, Vijyendra Ramesh, Fangchao Wei, Jason W. Locasale · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  47. Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models
    Ashley V. Schwartz, Grace Chao, Mikella Robinson, Brittany M. Conley, Mowaffaq Adam Ahmed Adam, Grace A. Wells, An D. Hoang, Elene Albekioni, Cecilia Gallo, Joi L. Weeks et al. · 2025 · Journal of Biological Chemistry
  48. Cancer Metabolism Meets DNA Repair: The Hidden Link to Therapy Resistance
    Chunzhang Yang · 2025 · BioEssays
  49. The oncometabolite R-2-hydroxyglutarate inhibits microglial activation via the FTO/NF-κB pathway
    Lu Wang, Huiting Zhang, Xifeng Jing, Yuanchi Huang, Yuxin Kang, Yulan Qian, Dong Chen · 2025 · Frontiers in Oncology
  50. Research on Targeted Therapy for Malignant Tumors of the Biliary Tract
    Yuxin Yang, Hutianyu Zhong, Jingjing Zhang, Peng Wang · 2026 · OncoTargets and Therapy
  51. HOT mutation screening in human glioblastomas
    Daniel Krell, Paul James Mulholland, Justin Stebbing, Ian P.M. Tomlinson, Chiara Bardella · 2015 · Future Science OA
  52. Status of IDH mutations in chondrosarcoma of the jaws
    Z. You, J. Zhang, Hong‐Tu Zhang, X. Li, Zhipeng Sun, Li Sun · 2022 · International Journal of Oral and Maxillofacial Surgery
  53. Understanding the Crosstalk Between Epigenetics and Immunometabolism to Combat Cancer
    Anuradha Seth, Susanta Kar · 2022 · Sub-cellular biochemistry/Subcellular biochemistry
  54. Targeting the IDH1R132H mutation in gliomas by CRISPR/Cas precision base editing
    Remi Weber, Flavio Vasella, Artsiom Klimko, Manuela Silginer, Martine L.M. Lamfers, Marian Christoph Neidert, Luca Regli, Gerald Schwank, Michael Weller · 2024 · Neuro-Oncology Advances
  55. Epigenetic and Immune Profile Characteristics in Sinonasal Undifferentiated Carcinoma
    Hyang Joo Ryu, Chung Lee, Sun Och Yoon · 2024 · Cancer Medicine
  56. Therapy enhancing chromosome instability may be advantageous for IDH1R132H/WT gliomas
    Nikolay V Goncharov, Ivan Baklanov, Valeriia S. Gulaia, Anastasiia P Shuliak, Daria Lanskikh, Valeriia Zhmenia, Mikhail E. Shmelev, Nikita A. Shved, Jing Wu, Mikhail A. Liskovykh et al. · 2025 · NAR Cancer
  57. RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
    Leslie C. Amorós Morales, Santiago M. Gómez Bergna, Abril Marchesini, María Luján Scalise, Nazareno González, María Leticia Ferrelli, Marianela Candolfi, Vı́ctor Romanowski, Matías L. Pidre · 2025 · International Journal of Molecular Sciences
  58. Prognostic significance of PD-L1 and CD45RO+ cells in glioblastoma: The modulating role of MMR status
    Yousef Mohammadi, Elina Kaviani, Simin Ahmadvand, Amirreza Dehghanian, Abbas Ali Ghaderi · 2025 · Journal of Neuroimmunology
  59. BAT mitochondria: whitening meets softening
    Mateus Prates Mori, Oswaldo A. Lozoya, Janine Hertzog Santos · 2025 · Nature Metabolism
  60. What's in the “fold”?
    Parul Mehra, Anuradha Kalani · 2018 · Life Sciences
  61. MYC Regulation of Metabolism and Cancer
    Arvin M. Gouw, Annie Lee Hsieh, Zachary E. Stine, Chi Van Dang · 2015 · Springer eBooks
  62. Novel therapeutic strategies in myelodysplastic syndromes
    Stephen S. Chung · 2016 · Current Opinion in Hematology
  63. Zaburzenia metabolizmu i funkcji enzymów metabolicznych a proces nowotworzenia
    Elzbieta A. Sarnowska, M. Leszczynski, Ewelina Macech-Klicka, Malgorzata Stachowiak, JANUSZ ALEKSANDER SIEDLECKI · 2016 · Nowotwory Journal of Oncology
  64. Genetics of glioma
    Landon John Hansen, Bill H. Diplas, Oren Josh Becher, Hai Yan · 2016 · Cambridge University Press eBooks
  65. Interaction Between Cellular Metabolic States and Chromatin Dynamics
    Samantha J Linder, Raúl Mostoslavsky · 2016 · Elsevier eBooks
  66. The leukaemia epigenome targeted
    Julie-Aurore Losman · 2017 · Nature
  67. Connecting Phytochemicals, Epigenetics, and Healthy Aging
    Katarzyna Szarc vel Szic, Ajay Palagani, Chandra Sekhar Chirumamilla, Jolien Diddens, Wim Vanden Berghe · 2013 · Elsevier eBooks
  68. Pathology of Primary Brain Tumors—Gliomas
    Derek Wong, Stephen S. F. Yip · 2019 · Elsevier eBooks
  69. The return of quiescence metabolites
    Hilary A. Coller · 2021 · Nature Cell Biology
  70. 1 Yeast as a Model for Systems Biology Studies on Complex Diseases
    Juan Ignacio Castrillo, Stephen G. Oliver · 2014 · Springer eBooks
  71. Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia
    Sonja Pavlović, Nataša Tos̆ić · 2019 · Europeanization and globalization
  72. New therapeutic options in myelodysplastic syndrome: literature review and single-center treatment results
    Elena Vladislavovna Morozova, Nikolay Tcvetkov, Irina Turtanova, Ivan Moiseev · 2021 · Cellular Therapy and Transplantation
  73. The role of epigenetics in cancer metastasis
    Madeline Farmer, Kristina Redd, Tinsley Roberson, Metta Smith, Kayla A. Lewis · 2022 · Elsevier eBooks
  74. A bacterial enzyme may correct 2-HG accumulation in human cancers
    William J. Yin · 2023 · Frontiers in Oncology
  75. l ‐2‐Hydroxyglutarate contributes to tumor radioresistance through regulating the hypoxia‐inducible factor‐1α signaling pathway
    Manman Zhang, Y J Liu, Xinran Lu, Liqing Du, Ningning He, Huijuan Song, Jinhan Wang, Yeqing Gu, Mengmeng Yang, Chang Xu et al. · 2024 · Journal of Cellular Physiology
  76. A patent review of IDH1 inhibitors (2018-present)
    Qing Liang, Fei Wen, Peilin Wang, Yong Jiang, Yuting Geng, Xiaoming Zha · 2025 · Expert Opinion on Therapeutic Patents
  77. Cancer metabolism rewiring and chromatin methylation: a vulnerable epi-metabolic link
    Sandra Atlante, Veronica Barbi, Carlo Gaetano, Barbara Illi · 2025 · Frontiers in Epigenetics and Epigenomics
  78. BCOR ‐Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study
    Diego M. Montoya‐Cerrillo, Mark Gordon Evans, Andrew J. Elliott, Renzo J. C. Calderon-Anyosa, Jaylou Velez Torres, Elizabeth Anne Montgomery, Francis John Hornicek, Harry Thomas Temple, Brooke Crawford, Jonathan C. Trent et al. · 2025 · Genes Chromosomes and Cancer
  79. Effects of short- and long-term mutant IDH1 inhibition on radiosensitivity across genetically diverse patient-derived IDH1-mutant glioma cells
    Yosuke Kitagawa, Logan Muzyka, Ami Kobayashi, Ethan Wetzel, Ali M. Nasser, Julie J. Miller, Hiroaki Wakimoto, Daniel P. Cahill · 2026 · Neuro-Oncology Advances
  80. Therapeutic targeting of tricarboxylic acid cycle and oxidative phosphorylation: a critical analysis of metabolic interventions in cancer treatment
    Yawei Han, Yuhao Wei, Yuanting Xie, Mengzhu Zheng · 2026 · Biochemical Pharmacology
  81. Metabolites in the tumor microenvironment: Key drivers of immune cell fate and function as therapeutic targets in cancer
    Xiao-Ping Zhao, Chu-Tian Mai, Yilin Zhao, Xin-Yi Zhou, Nian-Hong Lai, Xiao-Jun Zhang, Xing‐Xing Fan · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  82. IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma
    Eleni Panagioti, Hunter J. Kelley, Alexander Lee Ling, Leinal Sejour, Shikha Saini, William F. Goins, Daniel Roberts, Sotiris Sotiriou, Julian Bryan Iorgulescu, Karen Olivia Dixon et al. · 2026 · Nature Communications
  83. Metabolic alterations in the tumor microenvironment influence the anti-tumor immune function of CD8 + T cells via epigenetic modifications
    Yaru Liu, Wei Du, Weimin Deng · 2026 · International Reviews of Immunology
  84. Inhibitors of Jumonji C-Domain Histone Demethylases
    Peter Staller · 2015 · Elsevier eBooks
  85. Molecular basis of polycythemic disorders due to aberrant hypoxia sensing and its relevance to acute leukemia
    Josef T. Prchal · 2012 · Best Practice & Research Clinical Haematology
  86. Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
    Noelyn Anne Hung, Janice A. Royds, Tania L. Slatter · 2013 · Current molecular imaging
  87. Isocitrate Dehydrogenase (IDH) Mutation in Gliomas
    Charles Chesnelong · 2015 · Springer eBooks
  88. Targeted Therapy of IDH1-Mutated Tumors
    Owen Clark, Christian Grommes · 2016 · Springer eBooks
  89. Cancer Metabolism
    Daniel Richard Wahl, Sriram Venneti · 2017 · Springer eBooks
  90. Oncometabolite L-2-Hydroxyglutarate Promotes Oncogenesis of Renal Cell Carcinomas by Down-Regulating Differentiation
    Mary L. Taub · 2022 · IntechOpen eBooks
  91. Synthesis and in silico study of 2,4-diphenylquinolines as potential KDM4B protein inhibitors
    Dayana Orosco, Gustavo Adolfo Barraza, Carlos E. Puerto Galvis, Vladímir V. Kouznetsov, Carlos Mario Meléndez · 2023 · New Journal of Chemistry
  92. The antitumor action of endocannabinoids in the tumor microenvironment of glioblastoma
    Yi Wen Tang, Maoru Wang, Jiangping Yu, Guangyao Lv, Yu Wang, Bin Yu · 2024 · Frontiers in Pharmacology
  93. Resolving challenges in detection and quantification of D-2-hydroxyglutarate and L-2-hydroxyglutarate via LC/MS
    Tyrone Dowdy, Mioara Larion · 2026 · Methods
  94. Advances and insights in cancer metabolism and epigenetic reprogramming
    Yirong Zeng, Pu Wang, Dan Ye · 2025 · Chinese Science Bulletin (Chinese Version)
  95. In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903
    Zeen Tong, Usha Yerramilli, Sylvia Y.M. Yao, James D. Young, Matthew Hoffmann, Sekhar Surapaneni · 2018 · Xenobiotica
  96. THE GENETIC MARKERS OF MALIGNANT GLIOMAS
    Карташев Артем Владимирович, E I Yakubovich · 2016 · Medical academic journal
  97. Epigenetics and Epigenetic Therapy of Cancer
    Omotayo O. Fasan, Patrick McKay Boland, Patricia Lamont Kropf, Jean‐Pierre J. Issa · 2015
  98. Discovery and Development of Ivosidenib (AG‐120: TIBSOVO ® )
    Zenon D. Konteatis, Zhihua Sui · 2021
  99. A peptide-centric local stability assay to unveil protein targets of diverse ligands
    Kejia Li, Shijie Chen, Keyun Wang, Yan Wang, Zheng Fang, Jiawen Lyu, Haiyang Zhu, Yanan Li, Ting Yu, Feng Yang et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  100. Role of RIPK1 in Diffuse Gliomas pathology
    Leslie C. Amorós Morales, Santiago M. Gómez Bergna, Abril Marchesini, Ma. Luján Scalise, Nazareno González, Marianela Candolfi, Vı́ctor Romanowski, Matías L. Pidre · 2023 · bioRxiv (Cold Spring Harbor Laboratory)